Skip to main content

Table 2 Baseline characteristics divided in ACE pre-treatment and no ACE pre-treatment.

From: Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation

 

No ACE pre-treatment

ACE-pre-treatment

P

 

N = 79

N = 28

 

Duration in days, median (range)

   

   current episode

121 (74–178)

96 (59–135)

ns

   total AF duration

161 (105–247)

117 (63–160)

ns

Number of previous ECVs, N(range)

1 (0–5)

1(0–3)

ns

Underlying heart disease * (%)

   

   Left ventricular dysfunction

14%

40%

0.01

   Hypertension

24%

46%

0.03

   Valve disease

19%

21%

ns

   Coronary artery disease

18%

36%

0.07

   Lone AF

17%

14%

ns

Echocardiography (mm ± SD)

   

   LA parasternal long axis

46 ± 7

50 ± 10

0.03

   LA 4 chamber view long axis

66 ± 9

67 ± 12

ns

   LA 4 chamber view short axis

45 ± 8

49 ± 10

ns

   RA 4 chamber view long axis

61 ± 8

64 ± 7

ns

   LVEDD

49 ± 7

54 ± 8

0.01

   LVESD

34 ± 9

38 ± 12

ns

Medication

   

   Beta blocker

51%

47%

ns

   Calcium channel blocker

35%

39%

ns

   Digoxin

45%

51%

ns

   Diuretics

29%

34%

ns

   Angiotensin receptor blocker

1%

0%

ns

  1. * more then 1 entity per patient
  2. AF = atrial fibrillation, ECV = electrical cardioversion, LA = left atrium, RA = right atrium, LVEDD = left ventricular end diastolic diameter, LVESD = left ventricular end systolic diameter